All
FDA Grants Priority Review of Sorafenib for Rare Thyroid Cancer
Sorafenib (Nexavar) has been granted a priority review designation by the FDA for locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.
Monitoring CA-125 Shows Promise as a Screening Tool for Ovarian Cancer
Measuring CA-125, the protein that predicts ovarian cancer recurrence, has shown promise as a screening tool for the disease.
Mechanism of Action: Zoledronic Acid (Zometa)
Metastasis to bone is a common and serious complication of many solid tumors. Learn more about the mechanism of action of zoledronic acid (Zometa).
Ruxolitinib Improves Survival When Given with Capecitabine in Recurrent or Refractory Pancreatic Cancer
The survival rate of patients with recurrent or treatment-refractory pancreatic cancer was improved when patients were treated with a combination of ruxolitinib and capecitabine.
Study Suggests Pazopanib Causes Fewer Side Effects Than Sunitinib in Renal Cell Carcinoma
Pazopanib was better tolerated with noninferior efficacy when compared to sunitinib as a treatment for patients with advanced renal cell carcinoma.
Chemoresponse Assay Demonstrates Utility in Recurrent Ovarian Cancer
A study shows that a new chemoresponse assay improves the overall survival and progression-free survival of patients with recurrent ovarian cancer while helping clinicians individualize care for those patients.
Breast Cancer Pathogenesis
Breast cancer pathogenesis may be driven by activation of steroid hormone receptors, like those for estrogen and progesterone, and may also be driven by receptor tyrosine kinases.
Investigational Immunotherapy Falters in Late-Stage Melanoma Trial
The investigational immunotherapy Allovectin (velimogene aliplasmid) failed to meet key endpoints in a phase III trial in patients with stage III/IV metastatic melanoma.
Necitumumab as First-Line Therapy Improves Overall Survival in Metastatic NSCLC
Necitumumab plus chemotherapy as a first-line therapy for patients with metastatic squamous NSCLC demonstrated an improvement in OS vs chemotherapy alone.
Mechanism of Action: Nintedanib (BIBF 1120)
Nintedanib (also known as Vargatef and BIBF 1120) is an oxindole-based, orally-available triple kinase inhibitor targeting the angiogenesis factors VEGF, PDGF, and FGF.
The Week of August 5 in Review
The week of August 5 in review, featuring articles and physician interviews on tamoxifen in BRCA-positive patients, advances in melanoma, and the MAGE-A3 protein in lung cancer.
Tamoxifen Lowers Risk of Contralateral or Secondary Breast Cancer in BRCA-Positive Patients
Tamoxifen significantly lowered the risk of contralateral or secondary breast cancer by more than half in patients with BRCA1/2 mutations.
Development of Bone Metastases in Men With Prostate Cancer
Men with non-metastatic prostate cancer are commonly treated with androgen deprivation therapy (ADT) for various reasons including biochemical relapse after primary therapy.
The Week of July 29 in Review
The week of July 29 in review, featuring stories and physician interviews on genetic testing, expanding anti-HER2 therapy, and nivolumab for the treatment of melanoma.
Mechanism of Action: Afatinib (BIBW 2992)
Afatinib is an FDA-approved pan-HER inhibitor for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
The Week of July 22 in Review
The week of July 22 in review, featuring stories and physician interviews on crizotinib in NSCLC, the G-200 vaccine for glioblastoma, and ibrutinib in non-Hodgkin lymphoma.
Death Receptors in Apoptotic Pathways
Studies have confirmed that dysregulation of apoptosis is implicated in the pathogenesis of many diseases. Deficient apoptosis is key in the development of cancer.
NCI Releases Largest-Ever Dataset of Genetic Variants in Cell Lines for Nine Types of Cancer
Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.
Ovarian Cancer Pathogenesis
The risk of developing ovarian cancer has been linked to several factors including family history, age, and pregnancy history. In the U.S., ovarian cancer accounts for 3% of all cancer in women.
FDA Approves Afatinib Plus Companion Diagnostic for Late Stage Non-Small Cell Lung Cancer
The FDA has approved the pan-HER inhibitor afatinib (Gilotrif), along with a companion diagnostic, to treat patients with metastatic NSCLC who express specific types of EGFR mutations.
The Week of July 8 in Review
The week of July 8 in review, featuring clinical articles and videos on targeting the PI3K and AKT pathways, ASCO's CancerLinQ program, and ibrutinib in CLL and MCL.
Study of Lenalidomide in Newly Diagnosed Multiple Myeloma Patients Reaches Primary Endpoint
A phase III study of Revlimid in combination with dexamethasone in patients with newly diagnosed multiple myeloma met its primary endpoint of PFS.
New Drug Application Filed for Ibrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
The FDA has received a new drug application for ibrutinib as a therapy for previously treated CLL and previously treated MCL.
Pertuzumab and Trastuzumab Regimen in Neoadjuvant Setting for HER2-Positive Early Stage Breast Cancer Granted Priority Review
If approved, this regimen would be the first neoadjuvant regimen ever approved for the treatment of cancer.
The Case of The Wild Kinase
Learn how Genentech researchers Shiva Malek and Georgia Hatzivassiliou worked together to solve a mystery and change cancer research.
Mechanism of Action: Herceptin (Trastuzumab)
The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.
The Week of June 24 in Review
The week of June 24 in review, featuring clinical articles and physician interviews on an FDA approval, crizotinib in NSCLC, sorafenib in DTC, and more.
FDA Approves Labeling Update for Dasatinib
The FDA approved an update to the product labeling for dasatinib (Sprycel), Bristol-Myers Squibb Company and Otsuka America Pharmaceutical announced on June 20.
High Response Rates to Ibrutinib Seen in CLL, MCL
Patients with chronic lymphocytic leukemia (CLL) and patients with mantle cell lymphoma (MCL) showed high response rates to therapy with ibrutinib.
Oncologists and Social Media: An Interview With Mike Thompson, MD, PhD
In advance of the 2013 ASCO Annual Meeting, Targeted Healthcare spoke with Mike Thompson, MD, PhD, about the use of social media in the field of oncology.
